Jade Biosciences Inc., a biotechnology company specializing in therapies for autoimmune diseases, announced plans to initiate a clinical study of its anti-APRIL monoclonal antibody, JADE101, in healthy volunteers in the latter half of 2025. This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and biomarker suppression of JADE101, specifically targeting APRIL and IgA. Interim results from this study are expected in the first half of 2026, which will aid in determining appropriate dosing for future studies in patients with IgA nephropathy (IgAN). Preclinical data, presented at the 62nd European Renal Association Congress, highlighted JADE101's potential for best-in-class efficacy with convenient dosing intervals. A conference call and webcast regarding these developments were held on June 9, 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。